

References

I-128

1. National Comprehensive Cancer Network (NCCN). Decitabine. NCCN Drugs and Biologics Compendium®. 2024.
2. Micromedex DrugDex Compendium®. 2024. Decitabine.
3. Liu F, Wang H, Liu J, et al. A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in < 60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features. *Cancer Med*. 2019; 8(11):5108-15.
4. Budden, T, Westhuizen, A, Bowden, N. Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma. *BMC Cancer*. 2018.18 (1): p.100.
5. Illangeswaran RSS, Das S, Paul DZ, Mathews V, Balasubramanian P. A personalized approach to acute myeloid leukemia therapy: current options. *Pharmacogenomics & Personalized Medicine*. 2019;12:167-179.
6. Schroeder T, Rautenberg C, Krüger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. *Annals of Hematology*. 2018;97(2):335-342.
7. Dacogen (decitabine) for injection, for intravenous use [package insert]. Otsuka America Pharmaceutical, Inc. Rockville, MD. Revised 06/2020.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Decitabine.
9. Decitabine In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated November 1, 2006.
10. DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol*. 2020;7(10):e724-e736.